Pfenex“fully supports” partner Alvogen’s decision to launch the firms’ Bonsity (teriparatide) 505(b)(2) new drug application product in the US, as the clock ticks on a designation of therapeutic equivalence with Eli Lilly’s Forteo (teriparatide) reference brand.
Clock Ticks On Pfenex Teriparatide Equivalence Windfall
Key Date In October For Milestone Payment
Pfenex has less than two months for an “A” designation for therapeutic equivalence for to be granted for its Bonsity (teriparatide) 505(b)(2) product by the US FDA if it wishes to realize maximum value under the companies’ partnership agreement with Alvogen.
